Product Details
PMS-Azithromycin
Azithromycin600 mg
Tablet
DIN/PIN/NPN
02261642
Manufacturer
Pharmascience Inc.
Formulary Listing Date
2011-10-25
Unit Price
10.6652
Amount MOH Pays
10.6652
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
Antibiotics, Erythromycins (08:12:12): Erythromycin alone is not adequate for the treatment of H. influenzae infections. It lacks consistently reliable activity against this organism. Erythromycin is a potent inhibitor of hepatic oxidation of some drugs and may cause significant elevation of blood levels of astemizole, carbamazepine, cyclosporine, digoxin, dihydropyridines, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of erythromycin and astemizole or terfenadine.
ATC Code
J01FA10
Interchangeable Products
| DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
|---|---|---|---|
| 02231143 | Zithromax | NA | NA |
| 02261642 | PMS-Azithromycin | 10.6652 | 10.6652 |
LU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| 549 | 1 year | For the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infections |
EAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Unclassified EAP Drugs | These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding. |